Claims for Patent: 8,030,313

Summary for Patent: 8,030,313

Title:	Controlled release sterile injectable aripiprazole formulation and method
Abstract:	A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
Inventor(s):	Kostanski; Janusz W. (Princeton, NJ), Matsuda; Takakuni (Tokushima, JP), Nerurkar; Manoj (Monmouth Junction, NJ), Naringrekar; Vijay H. (Princeton, NJ)
Assignee:	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	11/979,149
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,030,313
Patent Claims:	1. A method of treating schizophrenia, which comprises administering to a subject in need of treatment thereof, a sterile injectable formulation obtained by reconstitution of a homogeneous suspension from a sterile freeze-dried controlled release aripiprazole formulation which comprises: (a) aripiprazole having a mean particle size of about 1 to 10 microns, and (b) one or more suspending agents, wherein said sterile freeze-dried controlled release aripiprazole formulation is in the form of a cake obtained by freeze-drying a homogeneous aqueous suspension comprising (a) and (b), and wherein upon reconstitution, which comprises adding water to said cake, the sterile injectable formulation is obtained which is a homogeneous suspension and which contains from about 0.1 to about 600 mg of aripiprazole per mL, and wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of at least about two weeks from the date of administration. 2. The method as defined in claim 1, wherein the sterile injectable formulation is administered intramuscularly or subcutaneously. 3. The method of treating schizophrenia as defined in claim 1, wherein the sterile freeze-dried controlled release aripiprazole formulation further comprises: (c) one or more bulking agents, and (d) one or more buffering agents. 4. The method as defined in claim 3, wherein the sterile injectable formulation is administered intramuscularly or subcutaneously. 5. The method of treating schizophrenia as defined in claim 3, wherein the sterile freeze-dried controlled release aripiprazole formulation comprises: (a) aripiprazole having a mean particle size of about 1 to 10 microns, (b) carboxymethyl cellulose or its sodium salt, (c) mannitol, (d) sodium phosphate to adjust pH to about 7, and (e) optionally sodium hydroxide to adjust pH to about 7, wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of at least about three weeks from the date of administration. 6. The method as defined in claim 5, wherein the sterile injectable formulation is administered intramuscularly or subcutaneously. 7. A method of treating schizophrenia, which comprises administering to a subject in need of treatment thereof, a sterile injectable formulation obtained by reconstitution of a homogeneous suspension from a sterile freeze-dried controlled release aripiprazole formulation which comprises: (a) aripiprazole having a mean particle size of about 1 to 10 microns, and (b) one or more suspending agents, wherein said freeze-dried formulation is in the form of a cake obtained by freeze-drying a homogeneous aqueous suspension comprising (a) and (b), and wherein upon reconstitution, which comprises adding water to said cake, the sterile injectable formulation is obtained which is a homogeneous suspension and which contains from about 0.1 to about 600 mg of aripiprazole per mL, and wherein upon injection into a subject, said sterile injectable formulation releases aripiprazole over a period of at least about one week from the date of administration. 8. The method as defined in claim 7, wherein the sterile injectable formulation is administered intramuscularly or subcutaneously. 9. The method as defined in claim 1, wherein the sterile injectable formulation comprises from 100 to 400 mg aripiprazole/mL and is administered one to two times monthly. 10. The method as defined in claim 3, wherein the sterile injectable formulation comprises from 100 to 400 mg aripiprazole/mL and is administered one to two times monthly. 11. The method as defined in claim 5, wherein the sterile injectable formulation comprises from 100 to 400 mg aripiprazole/mL and is administered one to two times monthly. 12. The method as defined in claim 7, wherein the sterile injectable formulation comprises from 100 to 400 mg aripiprazole/mL and is administered one to two times monthly. 13. The method as defined in claim 1, wherein the aripiprazole has a mean particle size of about 2 to about 4 microns. 14. The method as defined in claim 1, wherein the aripiprazole has a mean particle size of about 2.5 microns. 15. The method as defined in claim 1, wherein the aripiprazole is in the form of anhydrous crystals or in the form of a monohydrate. 16. The method as defined in claim 15, wherein the aripiprazole is in the form of Aripiprazole Anhydride Crystals B or Aripiprazole Hydrate A. 17. The method as defined in claim 3, wherein the aripiprazole is in the form of anhydrous crystals or in the form of a monohydrate. 18. The method as defined in claim 17, wherein the aripiprazole is in the form of Aripiprazole Anhydride Crystals B or Aripiprazole Hydrate A. 19. The method as defined in claim 5, wherein the aripiprazole is in the form of anhydrous crystals or in the form of a monohydrate. 20. The method as defined in claim 19, wherein the aripiprazole is in the form of Aripiprazole Anhydride Crystals B or Aripiprazole Hydrate A. 21. The method as defined in claim 3, wherein said sterile injectable formulation comprises: (a) aripiprazole having a mean particle size of about 1 to about 10 microns in an amount within the range from about 1 to about 40%, (b) suspending agent in an amount within the range from about 0.2 to about 10%, (c) bulking agent in an amount within the range from about 1 to about 10%, and (d) buffering agent in an amount within the range from about 0.02 to about 2% to adjust the pH of the sterile injectable formulation within the range from about 6 to about 7.5, wherein all of the above % are % by weight/volume based on the volume of the sterile injectable formulation. 22. The method as defined in claim 3, wherein the suspending agent is selected from the group consisting of carboxymethylcellulose or its sodium salt, hydroxypropyl cellulose, hydroxypropylethyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone; the bulking agent is selected from the group consisting of mannitol, sucrose, maltose, lactose, xylitol and sorbitol; and the buffering agent is selected from the group consisting of sodium phosphate, potassium phosphate and TRIS buffer. 23. The method as defined in claim 5, wherein the sterile injectable formulation is selected from the group consisting of the following Formulations A, B and C: TABLE-US-00008 Formulation A Formulation B Formulation C aripiprazole having 100 mg 200 mg 400 mg a mean particle size of about 1 to 10 microns Carboxymethyl 9 mg 9 mg 9 mg Cellulose Mannitol 45 mg 45 mg 45 mg Sodium phosphate 0.8 mg 0.8 mg 0.8 mg Sodium qs to adjust qs to adjust qs to adjust Hydroxide pH to 7 pH to 7 pH to 7 Water for Injection qs to 1 mL qs to 1 mL qs to 1 mL. 24. The method as defined in claim 21, wherein the sterile injectable formulation comprises: (a) aripiprazole having a mean particle size of about 1 to about 5 microns in an amount within the range from about 1 to about 40%, (b) suspending agent in an amount within the range from about 0.2 to about 10%, (c) bulking agent in an amount within the range from about 1 to about 10%, and (d) buffering agent in an amount within the range from about 0.02 to about 2% to adjust the pH of the sterile injectable formulation to about 6 to about 7.5, wherein all of the above % are % by weight/volume based on the total volume of the sterile injectable formulation. 25. The method as defined in claim 24, wherein the sterile injectable formulation comprises: (a) aripiprazole having a mean particle size of about 2.5 microns in an amount within the range from about 5 to about 20%, (b) suspending agent in an amount within the range from about 0.5 to about 5%, (c) bulking agent in an amount within the range from about 4 to about 5%, and (d) buffering agent in an amount within the range from about 0.03 to about 1% to adjust the pH of the sterile injectable formulation to about 6 to about 7.5, wherein all of the above % are % by weight/volume based on the total volume of the sterile injectable formulation. 26. The method as defined in claim 14, wherein the aripiprazole having a mean particle size of about 2.5 microns has a particle size distribution as follows: 95%<20 microns 90%<15 microns 50%<10 microns 10%<2 microns. 27. The method as defined in claim 25, wherein the aripiprazole having a mean particle size of about 2.5 microns has a particle size distribution as follows: 95%<20 microns 90%<15 microns 50%<10 microns 10%<2 microns. 28. The method as defined in claim 1, wherein the sterile injectable formulation contains from about 50 to about 400 mg of aripiprazole per 2 mL. 29. The method as defined in claim 1, wherein the sterile injectable formulation contains from about 100 to about 200 mg of aripiprazole per mL. 30. The method as defined in claim 3, wherein the sterile injectable formulation contains from about 50 to about 400 mg of aripiprazole per 2 mL. 31. The method as defined in claim 3, wherein the sterile injectable formulation contains from about 100 to about 200 mg of aripiprazole per mL. 32. The method as defined in claim 5, wherein the sterile injectable formulation contains from about 50 to about 400 mg of aripiprazole per 2 mL. 33. The method as defined in claim 5, wherein the sterile injectable formulation contains from about 100 to about 200 mg of aripiprazole per mL. 34. The method as defined in claim 7, wherein the sterile injectable formulation contains from about 50 to about 400 mg of aripiprazole per 2 mL. 35. The method as defined in claim 7, wherein the sterile injectable formulation contains from about 100 to about 200 mg of aripiprazole per mL.